A Study of Oral LY317615 in Relapsed or Refractory Diffuse Large B-Cell Lymphomas.

计划入组 55 人 · 首次发布于 2002 年 8 月 6 日

Epcoritamab-CAR T Cells for Large B-cell Lymphomas

计划入组 31 人 · 首次发布于 2024 年 6 月 13 日

Patients With Relapsed or Refractory Diffuse Large B Cell Non Hodgkin Lymphomas

计划入组 11 人 · 首次发布于 2010 年 3 月 2 日

CAR T-cell therapy (relapsed/refractory B-ALL)

anti-BCMA CAR T-cell therapy (refractory or relapsed multiple myeloma)

anti-TriPRIL CAR T-cell therapy (relapsed or refractory multiple myeloma)

CARGO Therapeutics

United States

Nkarta

United States

Karyopharm Therapeutics

United States

Epcoritamab Approved for Relapsed or Refractory Diffuse Large B-Cell Lymphoma

FDA Approves Two Bispecific T-Cell Engagers for Relapsed/Refractory B-Cell Lymphomas

Glofitamab-gxbm (Columvi) Approved for Relapsed or Refractory Diffuse Large B-Cell Lymphoma